Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma - Wikidata - wikimedia - TriplyDB

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

http://www.wikidata.org/entity/Q35063100

about

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

http://www.wikidata.org/entity/Q35063100

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

@ast

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

@en

type

label

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

@ast

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

@en

prefLabel

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

@ast

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

@en

P1433

Q35063100-1C39C071-C483-4603-B205-A792C35183AD

P1476

Q35063100-FA53AD11-0A14-48F3-BDF2-CF5CAA78F8F5

P2093

Q35063100-489E4DEB-ECDB-43F0-A325-CC03857DF704

Q35063100-499B1A66-2A0E-4E68-BE90-E189DDAF6525

Q35063100-76E11EA5-51BC-4B82-92A7-8799F8F9F881

P2860

Q35063100-03C8FFAD-C17B-4669-B065-31538F3EF3E8

Q35063100-0FCA5A52-2FBC-4903-A42B-5B3018926292

Q35063100-21CBDC1D-4560-41ED-B76B-5A81FA2DB8FB

Q35063100-30191BB0-05BA-4A06-B97B-DE4281292947

Q35063100-41F77C92-F221-4778-A1B7-F920120805D2

Q35063100-529AC359-7402-4E00-984F-A34FE523B03D

Q35063100-803342FF-9E4B-4A95-9A21-8BBC04F4A7BE

Q35063100-88369323-1DF0-4D2F-BBD2-6F445E42BD30

Q35063100-B8B107FC-61F2-4210-BD85-58281B771D35

Q35063100-CD886620-A4FE-44FF-8068-120AC296034E

P304

Q35063100-A1B5311E-9F44-4C89-9A80-E3F134B7C7D5

P31

Q35063100-C0BCA8B6-390C-405D-8BF8-F8283B3DFD91

P356

Q35063100-30DA334A-26EA-4FD1-B53D-768C66107600

P433

Q35063100-8F8763E9-BE49-4BBF-B620-09722955F786

P478

Q35063100-20A161E3-5ECA-4EC8-ADB0-3C88BC200199

P577

Q35063100-48CC5B0F-2858-4AA4-956C-7F82960023FD

P698

Q35063100-BD6EC4B5-0527-40DD-8341-342016FB09B4

P932

Q35063100-5D599B91-3BE7-48DB-A498-F1A98592D941

P356

P1433

Hospital pharmacy

P1476

Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma

@en

P2093

Dominic A Solimando

http://www.w3.org/2001/XMLSchema#string

J Aubrey Waddell

http://www.w3.org/2001/XMLSchema#string

Samantha Bryant

http://www.w3.org/2001/XMLSchema#string

P2860

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

P304

25-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HPJ5001-025

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25684797

http://www.w3.org/2001/XMLSchema#string

P932

4321425

http://www.w3.org/2001/XMLSchema#string